1613405-04-1

Basic information

• Product Name: (E)-3-(1H-benzo[d]imidazol-2-yl)-1-phenylprop-2-en-1-one
• Synonyms: (E)-3-(1H-benzo[d]imidazol-2-yl)-1-phenylprop-2-en-1-one
• CAS NO: 1613405-04-1
• Molecular Weight: 248.284
• Mol File: 1613405-04-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (E)-3-(1H-benzo[d]imidazol-2-yl)-1-phenylprop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(1H-benzo[d]imidazol-2-yl)-1-phenylprop-2-en-1-one(1613405-04-1)
• EPA Substance Registry System: (E)-3-(1H-benzo[d]imidazol-2-yl)-1-phenylprop-2-en-1-one(1613405-04-1)

Safety Data

• Hazardous Substances Data: 1613405-04-1(Hazardous Substances Data)

Upstream product

• 3314-30-5 1H-benzoimidazole-2-carboxaldehyde 
• 98-86-2 acetophenone 
• 20913-05-7 (Benzoylmethylene)triphenylphosphorane 

Downstream Products

• 1613405-05-2 3-(1H-benzo[d]imidazol-2-yl)-5-methyl-1-phenylhexane-1,4-dione 
• 1613405-06-3 2-[2-isopropyl-1-(3-(2-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-1H-pyrrol-3-yl]-1H-benzo[d]imidazole 
• 1613405-08-5 1-(cyclopropylmethyl)-2-(2-isopropyl-1-(3-(2-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-1H-pyrrol-3-yl)-1H-benzo[d]imidazole 
• 1639123-26-4 1-(cyclopentylmethyl)-2-(2-isopropyl-1-(3-(2-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-1H-pyrrol-3-yl)-1H-benzo[d]imidazole trifluoroacetate 
• 1613405-07-4 1-benzyl-2-(2-isopropyl-1-(3-(2-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-1H-pyrrol-3-yl)-1H-benzo[d]imidazole 

Relevant articles and documents

Simulation results source for the identification of biological active compounds: synthesis, antimicrobial evaluation and SARs of three in one heterocyclic motifs

For comprehensive studies on drugs primarily in the form of biomimetic systems, electronic parameters are becoming essential tools in elucidating the structures of the investigated compounds. In this study we present the synthesis, characterization, and evaluation of biological potency of 4(a–g), 5(a–g), and 7(a–g) by conducting structure–activity relationship (SAR) studies. Further conducting density functional theory (DFT) simulation studies for entitled compounds 4(a–g), 5(a–g), and 7(a–g) allowed us to fully study the effect of the changes of electronic and molecular structures on their biological activity by demonstrating the role of frontier molecular orbitals, in particular LUMO. The electron withdrawing nitro group substituted compounds 5d and 7d have higher activity than all other active compounds. Thus, the results strongly suggest that the SARs are in good agreement with simulation studies.

Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site

K-Ras is one of the most frequently mutated signal transducing human oncogenes. Ras signaling activity requires correct cellular localization of the GTPase. The spatial organization of K-Ras is controlled by the prenyl binding protein PDEδ, which enhances Ras diffusion in the cytosol. Inhibition of the Ras-PDEδ interaction by small molecules impairs Ras localization and signaling. Here we describe in detail the identification and structure guided development of Ras-PDEδ inhibitors targeting the farnesyl binding pocket of PDEδ with nanomolar affinity. We report kinetic data that characterize the binding of the most potent small molecule ligands to PDEδ and prove their binding to endogenous PDEδ in cell lysates. The PDEδ inhibitors provide promising starting points for the establishment of new drug discovery programs aimed at cancers harboring oncogenic K-Ras.